Details of the Drug

General Information of Drug (ID: DMIUYFH)

• Drug Name: Sulfapyridine
• Synonyms: Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Dermatitis herpetiformis	EB44	Approved	[1], [2]

• Therapeutic Class: Dermatologic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 249.29
  Topological Polar Surface Area (xlogp); 0
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption: The absorption of drug is 60-80% [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 14 hours [4]
  Metabolism: The drug is metabolized via the hepatic [3]
• Chemical Identifiers:
  Formula: C11H11N3O2S
  IUPAC Name: 4-amino-N-pyridin-2-ylbenzenesulfonamide
  Canonical SMILES: C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N
  InChI: InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
  InChIKey: GECHUMIMRBOMGK-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5336
  ChEBI ID: CHEBI:132842
  CAS Number: 144-83-2
  DrugBank ID: DB00891
  TTD ID: D0D4CY
  INTEDE ID: DR1512

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Inhibitor	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
RNA cytidine acetyltransferase (hALP) Main DME	DEZV4AP	NAT10_HUMAN	Substrate	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 000159.
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
• [6] Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009 Sep;407(1-2):30-5.
• [7] Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
• [8] A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
• [9] Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
• [10] Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
• [11] Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
• [12] Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
• [13] NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
• [14] Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
• [15] Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
• [16] Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
• [17] In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
• [18] Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
• [19] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [20] Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
• [21] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [22] Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
• [23] Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
• [24] Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.